A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ADAPTIVE, PARALLEL GROUP CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RMC-035 IN SUBJECTS AT HIGH RISK FOR ACUTE KIDNEY INJURY FOLLOWING OPEN-CHEST CARDIAC SURGERY
- Registry ID
- 21-ROS-05
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GUARD THERAPEUTICS INTERNATIONAL AB
- Start date
- 2022-12-01
- Last update
- 2022-01-11
Conditions
Related clinical trials
- AUTO-PLTS: THE EFFECTIVENESS OF AUTOLOGOUS, COLD-STORED PLATELETS
COLLECTED 7-10 DAYS BEFORE CARDI-AC SURGERY FOR AVOIDANCE OF
ALLOGENEIC TRANSFUSIONS: A RANDOMIZED PATIENT PREFERENCE TRIAL
- A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP
DOSE-FINDING CLINICAL STUDY TO EVALUATE THE EFFICACY ON RENAL FUNCTION, AND
SAFETY, OF RMC-035 IN PARTICIPANTS AT HIGH RISK FOR KIDNEY INJURY FOLLOWING
OPEN-CHEST CARDIAC SURGERY
- A RANDOMIZED, MULTI-CENTRIC, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF TIN816 IN ADULT PATIENTS AT RISK FOR ACUTE KIDNEY INJURY FOLLOWING CARDIAC SURGERY
- ARTEMIS: RAVULIZUMAB TO PROTECT PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) FROM CARDIAC SURGERY ASSOCIATED ACUTE KIDNEY INJURY (CSA-AKI) AND SUBSEQUENT MAJOR ADVERSE KIDNEY EVENTS (MAKE): A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY
- FACTOR REPLACEMENT IN SURGERY - FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE VERSUS FROZEN PLASMA IN BLEEDING ADULT CARDIAC SURGICAL PATIENTS (¿FARES-II¿ STUDY)
- A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BOTULINUM TOXIN TYPE A (AGN-151607) INJECTIONS INTO THE EPICARDIAL FAT PADS TO PREVENT POST-OPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING OPEN-CHEST CARDIAC SURGERY
View on source registry